Last update Feb. 5, 2025
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Etofenamate in other languages or writings:
Etofenamate belongs to this group or family:
Main tradenames from several countries containing Etofenamate in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 21 (dermal) | % |
Molecular weight | 369 | daltons |
Protein Binding | 99 | % |
Tmax | 2 - 5.6 | hours |
T½ | 1.6 - 3.3 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Nonsteroidal anti-inflammatory derived from flufenamic acid, which is its precursor. Topical use, although there are also oral and intramuscular forms of administration.
It is excreted in breast milk in negligible quantity: after an oral dose of 300 mg, less than 14 picograms in total of flufenamic acid were excreted in milk. (Dell 1983)
Flufenamic acid passes into milk in a clinically insignificant amount and is considered by the American Academy of Pediatrics as a medication usually compatible with breastfeeding. (AAP 2001)
Plasma absorption through the skin has been proven (Bender 2001). Its high binding to plasma proteins makes it unlikely to pass into milk.
If used, do not apply to the breast or to large areas or for prolonged periods to avoid systemic absorption.
See below the information of this related product: